17 results about "Blood Coagulation Factor X" patented technology

There has been demand for a pharmaceutical composition containing blood coagulation factor X in which the amount of FXa is suppressed. Provided is a pharmaceutical composition containing blood coagulation factor X, the pharmaceutical composition furthermore containing antithrombin III.

Various bispecific antibodies that specifically bind to both blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.

An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and / or treated more effectively.

A pharmaceutical composition comprising blood coagulation factor X for use in the treatment of a subject having hemophilia type A is provided. The present invention relates to a pharmaceutical composition, which is a pharmaceutical composition comprising blood coagulation factor X for use in the treatment of a subject having hemophilia type A wherein the blood coagulation factor X is used in combination with a bispecific antibody that binds to activated blood coagulation factor IX and blood coagulation factor X.

The invention relates to the technical field of biomarkers, in particular to a biomarker influencing the intramuscular fat content of chicken and application of the biomarker. The invention relates to a biomarker for influencing the intramuscular fat content of chicken. The biomarker is a blood coagulation factor X. Experiments find that the blood coagulation factor X has significant difference in high intramuscular fat chicken and low intramuscular fat chicken, and can be used for identifying the intramuscular fat content of Gushi chicken and breeding the Gushi chicken with high intramuscular fat. The invention further provides application and a screening method of the serum biochemical marker, and a new thought is provided for local chicken breeding.

The application belongs to the technical field of mass spectrometry, and particularly relates to a mass spectrometry detection method and application of intracellular blood coagulation factor X, which comprises the following steps: specifically enriching ectopic synthesis of blood coagulation factor X in tumor cells to obtain a protein sample; performing protein sample fixation and treatment on the protein sample by using SDS-PAGE gel electrophoresis, placing the gel in an ice box after scanning the gel by using a gel imaging system, and storing the gel; performing in-gel enzymatic digestion on the blood coagulation factor X in the gel to obtain a peptide segment solution; detecting the endogenous synthesis of blood coagulation factor X in tumor cells by using mass spectrometry technology, and obtaining mass spectrometry data. The application firstly adopts the mass spectrometry technology to detect the blood coagulation factor X synthesized by tumor cells outside normal liver cells, specifically enriches the ectopic synthesis of blood coagulation factor X in glioma cells by using the protein immunoprecipitation technology, performs SDS-PAGE gel electrophoresis, performs in-gel enzymatic digestion, and detects the endogenous synthesis of blood coagulation factor X in tumor cells by using the mass spectrometry technology.

An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and / or treated more effectively.

The present application relates to blood coagulation factor X activator (FX activator, e.g., RVV-X) compositions (e.g., pharmaceutical compositions) comprising sucrose, histidine, polysorbate 20, and mannitol, and the use of FX activator (e.g., RVV-X) or compositions thereof (e.g., pharmaceutical compositions) for the treatment of hemorrhagic diseases (e.g., hemophilia) in subjects (e.g., humans).

Provided is a pharmaceutical composition for treating a subject receiving treatment with a direct oral anticoagulant targeting activated blood coagulation factor X. This pharmaceutical composition contains activated blood coagulation factor VII and blood coagulation factor X and is for treating a subject receiving treatment with a direct oral anticoagulant targeting activated blood coagulation factor X.

To provide multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations thereof.SOLUTION: A bispecific antibody has a first antigen-binding site which binds to blood coagulation factor IX (FIX) and / or activated blood coagulation factor IX, and a second antigen-binding site which binds to blood coagulation factor X, where, the FIX activation-inhibiting activity is not elevated and the FVIII cofactor function-substituting activity is elevated. There are also provided pharmaceutical formulations thereof.SELECTED DRAWING: None

The application discloses use of a low molecular weight dextran sulfate derivative in preparation of an anticoagulant drug, the low molecular weight dextran sulfate derivative is shown as formula (I), wherein a main connection mode is an alpha-(1, 6)-glycosidic bond main chain, relates to a weight average molecular weight (M w )≤40 kDa, and each glucose unit has at least 1.0-2.0 sulfate groups on average, wherein the low molecular weight dextran sulfate derivative has a high selective inhibitory activity on a blood coagulation factor X enzyme, so as to inhibit an endogenous blood coagulation pathway; can effectively inhibit thrombosis in vivo and in vitro, and has potential as a novel endogenous anticoagulant.

To provide a multi-specific antigen-binding molecule having an alternative function to the function of blood coagulation factor VIII.SOLUTION: The present invention provides a multi-specific antigen-binding molecule with high activity substituting for the function of blood coagulation factor VIII. The molecule is found out among various prepared bispecific antibodies each specifically binding to both the blood coagulation factor IX / activated blood coagulation factor IX and the blood coagulation factor X and having an alternative function to the cofactor function of the blood coagulation factor VIII, i.e., the function of promoting the activation of the blood coagulation factor X by the activated blood coagulation factor IX.SELECTED DRAWING: None

The invention relates to the technical field of biomarkers, in particular to application of a blood coagulation factor X as a biomarker influencing the abdominal fat percentage of chicken. The invention discloses a biomarker influencing the abdominal fat percentage of chicken. The biomarker is a blood coagulation factor X. Experimental data provided by the invention show that F10 shows a significant difference (Plt; P1t) between groups with high abdominal fat percentage (AFP > = 18%) and groups with low abdominal fat percentage (AFP < = 12%); 0.05), and the biochemical marker combination can be used as a specific molecular marker for the abdominal fat mass of the Gushi chicken. On the basis, a molecular marker assisted breeding system containing serum F10 concentration detection, TG level evaluation and phenotype data association analysis is established, and an innovative technical path is provided for high-quality breeding of Henan local chicken germplasm resources.

The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and / or activated blood coagulation factor IX and blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and / or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII can be prevented and / or treated more effectively.

The invention discloses a method for purifying and activating prothrombin, which comprises the following steps: by taking cryoprecipitate-removed plasma as a raw material, washing and eluting by adopting an anion exchange resin adsorption method to obtain a solution containing the prothrombin and a blood coagulation factor X (FX), carrying out ultrafiltration on the solution to reduce the conductivity to be below 2.5 ms / cm, and concentrating the concentration of the prothrombin to be above 15IU / ml to obtain the prothrombin. And adjusting the concentration of FX to 50%-150% of the concentration of prothrombin. Adjusting the concentration of the prothrombin, adding a calcium chloride solution into the prothrombin until the final concentration of calcium chloride in the solution is 20-60mmol / l, uniformly stirring and mixing, and activating for 6-15 days at the temperature of 0-8 DEG C to obtain a thrombin solution. According to the method, the prothrombin recovery rate is high, the activation effect is good, and each IU of prothrombin can be activated to obtain 207.5 IU of thrombin titer. The problem that the thrombin titer recovery rate is not high is solved, and the yield of unit plasma thrombin titer is greatly increased.

The present application relates to blood coagulation factor X activator (FX activator, e.g., RVV-X) compositions (e.g., pharmaceutical compositions) comprising sucrose, histidine, polysorbate 20, and mannitol, and the use of FX activator (e.g., RVV-X) or compositions thereof (e.g., pharmaceutical compositions) for the treatment of hemorrhagic diseases (e.g., hemophilia) in subjects (e.g., humans).

[Problem] To provide: an agent that is used for the improvement or suppression of hemosiderin deposition and / or synovial membrane thickening or the like; a use of an antigen-binding molecule for the above-mentioned improvement or suppression; and others. [Solution] It has been found that a multispecific antigen-binding molecule capable of recognizing blood coagulation factor IX and / or activated blood coagulation factor IX and also capable of recognizing blood coagulation factor X and / or activated blood coagulation factor X is effective for the improvement and / or suppression of hemosiderin deposition and / or synovial membrane thickening or the like in joints. The present invention provides: an agent that is used for the improvement or suppression of hemosiderin deposition and / or synovial membrane thickening or the like, the agent comprising the multispecific antigen-binding molecule; a use of the molecule for the above-mentioned improvement or suppression; and others.